Merck Stock Slips 1.5% as $400 Million Buys KRAS Rights
Merck NYSE:MRK, the cancer drug and vaccine maker, fell about 1.5% to $146.48 around 11:08 a.m. ET Tuesday after agreeing to pay $400 million upfront for a potential new cancer treatment. The deal adds to Merck's pipeline, but investors are paying for a drug candidate that has yet to reach human te…